AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04308811 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: platelet rich plasma
Description: Platelet rich plasma and intrauterine balloon applied intrauterine after hysteroscopic adhesiolysis of intrauterine adhesions
Study NCT04308811 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: amniotic membrane graft group
Description: amniotic membrane applied on the intrauterine balloon after hysteroscopic lysis of intrauterine adhesions
Study NCT04308811 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Intrauterine balloon
Description: intrauterine balloon applied intrauterine after hysteroscopic lysis of intrauterine adhesions
Study NCT03001934 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: Registration of all NS patients in the First Affiliated Hospital of Sun Yat-sen University and other hospitals which have signed the contract in China.
Study NCT04296123 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Step training
Description: A 12-week step training consisting of two 30-minute training session per week. The participants will be instructed to stand upright and step on different targets on a plastic mat repeatedly.
Study NCT02364986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rebif®
Description: Rebif® 44µg (day 1, 3, 5 and 8) s.c.
Study NCT02364986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avonex
Description: Avonex 30µg (day 1 and 8) i.m.
Study NCT01911429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurasidone 40 mg
Description: Lurasidone 40 mg once daily
Study NCT01911429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurasidone 80 mg
Description: Lurasidone 80 mg once daily
Study NCT01911429 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 40 or 80 mg
Description: Placebo 40 or 80 mg once daily
Study NCT03659565 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Pre-Visit Consultation
Description: The Intervention Group will be given access to the optimized personal health record and will use Zoom as part of the pre-visit consultation.
Study NCT03659565 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Control
Description: Caregivers and patients will participate in usual pre-visit process.
Study NCT06627023 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implant Placement with Conical or Butt-Joint Connection
Description: Thirty eight patients were enrolled in the study and received randomly allocated implants with conical and butt-joint implant-abutment connection type. A standard healing abutment was placed after 6 months for two weeks. The definitive screw retained crowns were manufactured in a digital workflow. The soft tissue profile was digitized using IOS on following stages: pre-op, post-op: immediately, two, 7 and 14 days, pre-exposure, immediately after exposure, two weeks after exposure (pre-delivery), immediately after crown delivery, 6 and 12 months post-op.
Study NCT01216865 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: umbilical cord mesenchymal stem cells
Description: 5\*10/7 per ischemic limb
Study NCT01216865 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Therapy
Description: Any thing directed to improve blood perfusion in the limb example.Heparin,Antiplatelet agents etc
Study NCT02046863 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated Programming
Description: Prototype DBS-Expert software will be used to guide a clinician through DBS programming.
Study NCT01717950 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Na-APR-1 (M74)/Alhydrogel®
Description: The Na-APR-1 (M74) candidate vaccine contains the recombinant Na-APR-1 (M74) protein expressed by Nicotiana plants. Purified Na-APR-1 (M74) was subsequently adsorbed onto aluminum hydroxide gel (Alhydrogel®) and suspended in a solution containing 10 mM imidazole, 150 mM sodium chloride and 0.3% Empigen BB, with pH 7.4 ± 0.1. The final concentration of Na-APR-1 (M74) in the drug product is 0.1 mg/ml, whereas that of Alhydrogel® is 0.8 mg/ml. Different doses of Na-APR-1 (M74) will be delivered by injecting different volumes of the 0.1 mg/ml Na-APR-1 (M74) preparation.
Study NCT01717950 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gluco-Pyranosylphospho-Lipid A Aqueous Formulation
Description: GLA-AF contains a synthetic monophosphoryl lipid A (MPL) molecule that has Toll-Like Receptor-4 agonist activity. MPL is itself derived from the lipopolysaccharide (LPS) of Salmonella minnesota, a natural TLR4 agonist that is pyrogenic and can induce toxic shock. LPS, and more specifically, its lipid A component, has long been known for its strong adjuvant effects; however, its high toxicity has precluded its use in a vaccine formulation.
Study NCT03040895 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group-based ICDP-intervention
Description: Group-based ICDP-intervention for caregivers through a sequence of eight meetings
Study NCT03040895 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as usual
Description: Treatment as usual through the data collection period (6 months)
Study NCT05128396 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Stimulation
Description: During the initial session, a member of the research team will visit the subject's home and introduce the subject to the Cogmed training program (www.cogmed.com). Individuals will start at the same low difficulty level. As training proceeds, task difficulty will be individually adjusted based on performance by increasing/decreasing the number of items individuals have to remember, such that a participant reaches approximately 60% correct per day for each task. Each training session will start at the task difficulty level where the participant ended in the previous session. Performance and reaction time data will be continuously recorded while subjects are doing the task, and these data will be sent via the internet to the research team after each session. A member of the research team will communicate with each subject on a weekly basis (via phone call or email) to provide feedback and address any questions or concerns.
Study NCT05128396 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness training
Description: The mindfulness meditations will be narrated by one guide and the tasks will be narrated by a different guide. We will have 7 mindfulness tasks in total, whose order of presentation will be counterbalanced across sessions: 1. mindful observing of place, 2. mindful eating, 3. mindful observing of object, 4. mindful observing of person, 5. mindful walking, 6. mindful listening, and 7. mindful writing with the non-dominant and dominant hand.~At the end of each session, participants will write brief reflections stored via the website (e.g., an estimate of the amount of time subjects experienced their thoughts as wandering) both as an integral part of the mindfulness process and as a means of increasing the likelihood that subjects fully participate in each session. Each session will be structured as follows: Login, Mindfulness Meditation Session, Mindfulness Task 1, Mindfulness Task 2, Mindfulness Task 3, Write Log Reflection, Logout.
Study NCT05128396 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity
Description: Aerobic exercises will include relatively low impact activities like walking, jogging, or running in place, which will aim to put limited demands on balance. Each exercise will be explained and demonstrated in the video. All exercises can be done standing, sitting, or next to a chair that provides balance support as demonstrated in the videos. After the first session, for each subsequent session the difficulty level will start at one level below the previous session's average difficulty level (e.g. if they exercise at the most difficult level for most of the time during one session, the next session will start at the medium difficulty level). Each exercise will be explained and demonstrated in the video.
Study NCT02213419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasonography-guided double ethanol lavage
Description: A radial echoendoscope and a 22 gauge needle were then used for cyst fluid aspiration and ethanol lavage.~The 80 percent volume of cyst fluid was aspirated, and the pure ethanol was injected into the collapsed cyst until the original shape was restored. After 3-5 minutes, the reaspiration of the injected ethanol was then performed. The pure ethanol was reinjected into the collapsed cyst, followed by reaspiration of maximal possible volume for 3-5 minutes.
Study NCT04018781 — intervention group
Intervention type: OTHER
Intervention: medication reconciliation
Description: During hospitalization, the hospital pharmacist will carry out a pharmaceutical analysis for all patients included in the study, each time the prescription is changed and within a maximum of 24 hours (working days).~If necessary, in consultation with the doctor in charge of the patient, the pharmacist may also propose a pharmaceutical interview to the patient at any time during his hospitalisation (e.g. proposal for the de-prescription of benzodiazepines, Proton Pump Inhibitors, etc., according to the recommendations in force).
Study NCT05128396 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: Individuals in the control group will participate in the same computerized Cogmed training program as described above. The main difference is that for the control group task difficulty will remain at the same low starting level, rather than increasing over time. The instructions given to subjects will be identical to the ones used in the cognitive training intervention.
Study NCT02054715 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: print educational intervention
Description: print educational intervention
Study NCT02054715 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: multimedia psychoeducational intervention
Description: multimedia psychoeducational intervention
Study NCT01330043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: Both groups received the same pharmacotherapy per protocol. During open label treatment, all received CBT and bupropion and NRT patch. At week 10 those who continued to smoke were switched to varenicline through week 26. At week 10 those who are abstinent and reported low levels of craving and low levels of depression symptoms were withdrawn from study medications. Those who were abstinent but reported difficulty with craving or depression symptoms remained on bupropion and NRT through week 26. Medication was not available after week 26.
Study NCT01330043 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion
Description: Both groups received the same pharmacotherapy per protocol. During open label treatment, all received CBT and bupropion and NRT patch. At week 10 those who continued to smoke were switched to varenicline through week 26. At week 10 those who are abstinent and reported low levels of craving and low levels of depression symptoms were withdrawn from study medications. Those who were abstinent but reported difficulty with craving or depression symptoms remained on bupropion and NRT through week 26. Medication was not available after week 26.
Study NCT01330043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Description: Both groups received the same pharmacotherapy per protocol. During open label treatment, all received CBT and bupropion and NRT patch. At week 10 those who continued to smoke were switched to varenicline through week 26. At week 10 those who are abstinent and reported low levels of craving and low levels of depression symptoms were withdrawn from study medications. Those who were abstinent but reported difficulty with craving or depression symptoms remained on bupropion and NRT through week 26. Medication was not available after week 26.
Study NCT01330043 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine patch
Description: Both groups received the same pharmacotherapy per protocol. During open label treatment, all received CBT and bupropion and NRT patch. At week 10 those who continued to smoke were switched to varenicline through week 26. At week 10 those who are abstinent and reported low levels of craving and low levels of depression symptoms were withdrawn from study medications. Those who were abstinent but reported difficulty with craving or depression symptoms remained on bupropion and NRT through week 26. Medication was not available after week 26.
Study NCT01330043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Both groups received the same pharmacotherapy per protocol. During open label treatment, all received CBT and bupropion and NRT patch. At week 10 those who continued to smoke were switched to varenicline through week 26. At week 10 those who are abstinent and reported low levels of craving and low levels of depression symptoms were withdrawn from study medications. Those who were abstinent but reported difficulty with craving or depression symptoms remained on bupropion and NRT through week 26. Medication was not available after week 26.
Study NCT01330043 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: Both groups received the same pharmacotherapy per protocol. During open label treatment, all received CBT and bupropion and NRT patch. At week 10 those who continued to smoke were switched to varenicline through week 26. At week 10 those who are abstinent and reported low levels of craving and low levels of depression symptoms were withdrawn from study medications. Those who were abstinent but reported difficulty with craving or depression symptoms remained on bupropion and NRT through week 26. Medication was not available after week 26.
Study NCT04351750 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: general exercise
Description: The participants will receive training sessions twice a week for 8 weeks. General exercise includes aerobic exercise (stationary bike) and resistance training (thera-band, sandbags, dumbbell and swiss ball), and the intensity and progression of both aerobic and resistance exercises will be provided as recommended by the ACSM, and the exercise will individualized based on participant's HRR, 1 RM weight and Borg Scale of Perceived Exertion Scale (Borg RPE scale). An oximeter will be utilized to monitor the heart rate and SPO2 of the participants to ensure safety during the training session.
Study NCT04351750 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pelvic floor muscle training
Description: Participants will do pelvic floor muscle training in different positions. Each session includes three sets of eight to twelve maximum voluntary contractions of pelvic floor muscle, with holding the contraction for 6 to 8 seconds, and if possible, to do three fast contractions at the end of each set.
Study NCT04351750 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pelvic floor muscle training
Description: Participants will do pelvic floor muscle training in different positions. Each session includes three sets of eight to twelve maximum voluntary contractions of pelvic floor muscle, with holding the contraction for 6 to 8 seconds, and if possible, to do three fast contractions at the end of each set.
Study NCT03112122 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous bone marrow concentrate
Description: injection of autologous bone marrow concentrate
Study NCT03763227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab (IVR) injection
Description: Intravitreal ranibizumab (IVR) injection in patients with retinal dystrophy and macular cysts who have not responded to treatment with carbonic anhydrase inhibitors
Study NCT03763227 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbonic Anhydrase Inhibitor (CAI) therapy
Description: Carbonic anhydrase therapy (Oral or Topical) in patients with retinal dystrophy and macular cysts
Study NCT06687629 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Concha bullosa crushing
Description: Concha bullosa crushing
Study NCT06687629 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Concha bullosa resection
Description: Concha bullosa resection
Study NCT00941421 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: oesophagal videocapsule and oeso-gastro-duodenal fiberoptic endoscopy
Description: each patient receive one OVC and one OGDFE the same day
Study NCT03857152 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Contrast enhanced spectral mammography (CESM)
Description: Contrast enhanced spectral mammography (CESM) will be undertaken in addition to routine practice.~CESM is a specialist mammography test that aims to 'highlight' areas of concern within the breast in more detail than a standard mammogram.~The difference between CESM and a standard mammogram (x-ray of the breast) is the use of a special dye (called contrast medium) that is injected into the veins before the mammogram images are taken. The contrast enhanced images give more detailed information to the breast radiologists (expert doctors trained to analyse breast imaging).
Study NCT02127398 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: fecal microbiota
Description: fecal microbiota in capsule form
Study NCT00469261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: Doxycycline 100 mg bid for seven days after enrollment
Study NCT00469261 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Current medical therapy for AMI
Description: Current medical therapy for AMI
Study NCT03112122 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bone substitute i-FactorTM
Description: subchondral injections of i-FactorTM
Study NCT03112122 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: core decompression
Description: subchondral anterograde drilling
Study NCT03007901 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Climate Action
Description: Educational and Behavioral Training Curriculum: An article describing our proposed program was recently published in Sustainability (1) and is summarized here. Experienced instructors from the UW Integrative Medicine Mindfulness Program will teach the 8-week program. Classes will meet weekly for 2½ hours, with a 6 hour weekend retreat. Twenty to 45 minutes of daily home practice will be guided by audio recordings leading participants through body scan, sitting meditations, breath awareness, and mindful movement. Each of the 2½ hour weekly classes includes topics (\~30 min) relating to climate change, energy use, and carbon footprint.
Study NCT03927599 — intervention group
Intervention type: OTHER
Intervention: Data Collection
Description: Colleciton of data from medical records only
Study NCT01244360 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: resveratrol
Description: Subject will take resveratrol supplement for 4 weeks, with optional additional 4 week treatment period.
Study NCT01244360 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Sugar Pill
Description: Subject will take placebo for daily for 4 weeks, with optional additional 4 week treatment period.
Study NCT03122301 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stellate Ganglion Block injection with bupivicaine
Description: A computer-generated 1:1 block randomization scheme will be used to assign participants to receive either a SGB with bupivacaine or a sham injection with saline. Randomization will be performed by the injectionist immediately before the injection procedure by opening an opaque envelope to reveal the participant number and group assignment printed on an index card.
Study NCT03122301 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Saline
Description: sham injection with saline
Study NCT01172275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine
Description: 1 900mg tablet once a day for 1 week, then 1 900mg tablet twice a day for 1 week and then 1 900mg tablet three times a day for the remaining 10 weeks of the trial.
Study NCT01172275 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 900mg tablet once a day for 1 week, then 1 900mg tablet twice a day for 1 week and then 1 900mg tablet three times a day for the remaining 10 weeks of the trial. Children receiving placebo will be offered the active intervention after the double-blind portion of the trial.
Study NCT04539587 — intervention group
Intervention type: OTHER
Intervention: Quality of life
Description: The patient will receive the following questionnaires to be completed :~EORTC QLQ-C30 EORTC QLQ-BR23 EORTC SHQ-C22
Study NCT00209651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Campto, Topotesin
Description: q00 mg/m2, IV (in the vein) on day 1,15 of each 28 day cycle.
Study NCT00209651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-1
Description: 80 mg/m2, PO (oral) on day 1\~14 of each 28 day cycle.
Study NCT03843242 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pacemaker with Fixed long AV delay
Description: Fixed AV delay was applied in the first 3 months of pacemaker implantation according to previously proposed definition.
Study NCT03843242 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pacemaker with VpS® algorithm on
Description: 1. After first 3 months of pacemaker implantation, the patients will be randomized into two groups (Vp-suppression algorithm on group vs. IRS-plus algorithm on group) using a centralized randomization system.~2. In Vp-suppression algorhithm on group, Vp suppression algorithm of Enitra 8 DR-T pacemaker will be turned on at 3month visit after enrollment.~3. The patient will be followed at 3-month after enrollment and at 6-month and 12-month after applying the specific algorithm.